TY - JOUR
T1 - Clinical impact of Pancreatic metastases from renal cell carcinoma
T2 - A multicenter retrospective analysis
AU - Grassi, Paolo
AU - Doucet, Ludovic
AU - Giglione, Palma
AU - Grünwald, Viktor
AU - Melichar, Bohuslav
AU - Galli, Luca
AU - De Giorgi, Ugo
AU - Sabbatini, Roberto
AU - Ortega, Cinzia
AU - Santoni, Matteo
AU - Bamias, Aristotelis
AU - Verzoni, Elena
AU - Derosa, Lisa
AU - Studentova, Hana
AU - Pacifici, M.
AU - Coppa, Jorgelina
AU - Mazzaferro, Vincenzo
AU - De Braud, Filippo
AU - Porta, Camillo
AU - Escudier, B.
AU - Procopio, Giuseppe
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. In this analysis we evaluated the outcome of patients with pancreatic metastases treated with either targeted therapies or local treatment to the pancreas. Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and 2014 were identified from 11 European centers. Clinical records were retrospectively reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free survival and overall survival. Cox's proportional hazard models were used for survival analysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy. Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR 54-142). Disease control rate after first-line TTs was 84%, with a median progression-free survival of 12 months (95% CI 10-14). Median overall survival was 73 months (95% CI 61-86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106 months (95% CI 78-204) with a 5-year overall survival of 75%. On multivariable analysis, nephrectomy (HR 5.31; 95%CI 2.36-11.92; p
AB - Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. In this analysis we evaluated the outcome of patients with pancreatic metastases treated with either targeted therapies or local treatment to the pancreas. Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and 2014 were identified from 11 European centers. Clinical records were retrospectively reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free survival and overall survival. Cox's proportional hazard models were used for survival analysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy. Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR 54-142). Disease control rate after first-line TTs was 84%, with a median progression-free survival of 12 months (95% CI 10-14). Median overall survival was 73 months (95% CI 61-86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106 months (95% CI 78-204) with a 5-year overall survival of 75%. On multivariable analysis, nephrectomy (HR 5.31; 95%CI 2.36-11.92; p
UR - http://www.scopus.com/inward/record.url?scp=84963784539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963784539&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0151662
DO - 10.1371/journal.pone.0151662
M3 - Article
VL - 11
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 4
M1 - e0151662
ER -